Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
InSilico Medicine Cayman TopCo OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
InSilico Medicine Cayman TopCo OCF Yield % Related Terms
InSilico Medicine Cayman TopCo OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O15 vs MSFT, ORCL, PLTR: OCF Yield % Comparison
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo OCF Yield % vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's OCF Yield % distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (FRA:O15) has a OCF Yield % of -2.20 as of Aug. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #2109 out of 2875 companies in the Software industry, placing it in the top 73.4%.
Is InSilico Medicine Cayman TopCo's OCF Yield % too high?
InSilico Medicine Cayman TopCo's current OCF Yield % is -2.20. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #2109 out of 2875 companies in the Software industry, which is below the industry midpoint. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's OCF Yield % compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #2109 out of 2875 companies for OCF Yield %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median OCF Yield % is 3.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Software company?
The median OCF Yield % among Software companies is 3.07, based on 2,875 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median OCF Yield % is 3.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current OCF Yield % is -2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current OCF Yield % of -2.20. The current OCF Yield % is -2.20. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current OCF Yield % is -2.20 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
